RVTY — Revvity, Inc.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
- Exchange: NYSE
- Employees: 11,000
- Website: http://www.revvity.com
Latest SEC filings for RVTY
- 10-Q — 2026-08-11
- 8-K — 2026-08-04
- 11-K — 2026-06-23
- SD — 2026-06-01
- 10-Q — 2026-05-12
- 8-K — 2026-05-05
- 8-K — 2026-05-01
- ARS — 2026-03-16
- 10-K — 2026-02-24
- 8-K — 2026-02-02
Latest RVTY news
- — ELV vs. RVTY: Which Stock Is the Better Value Option? (Zacks Investment Research)
- — Revvity Launches Signals LabGistics to Coordinate Scientific Workflows (Zacks Investment Research)
- — Thermo Fisher to Report Q3 Earnings: What's in the Cards? (Zacks Investment Research)
- — Revvity to Present at Upcoming Investor Conferences (businesswire.com)
- — Revvity to Host Investor Day (businesswire.com)
- — Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks Investment Research)
- — Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock? (zacks.com)
- — Revvity to Hold Earnings Call on November 3, 2026 (businesswire.com)
- — North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity (GlobeNewswire Inc.)
- — Here's Why You Should Retain Revvity Stock in Your Portfolio for Now (zacks.com)
Educational tool only — not investment advice.